Signatera, Natera’s personalized test to detect residual signs of cancer in people with solid tumors, will be used in an upcoming Phase 2 trial as a tool to identify patients with early HR-positive (hormone receptor-positive), HER2-negative (human epidermal growth factor 2-negative) breast cancer who are at high risk of cancer relapse. The test also will be used to monitor the response of participants who do test positive for signs of residual disease to a combination therapy…
You must be logged in to read/download the full post.
The post Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial appeared first on BioNewsFeeds.